Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Aug;26(4):234-239.
doi: 10.3747/co.26.4869. Epub 2019 Aug 1.

Utility of a chemotherapy toxicity prediction tool for older patients in a community setting

Affiliations
Multicenter Study

Utility of a chemotherapy toxicity prediction tool for older patients in a community setting

C Mariano et al. Curr Oncol. 2019 Aug.

Abstract

Background: Expert groups have recommended incorporation of a geriatric assessment into clinical practice for older patients starting oncologic therapy. However, that practice is not standard primarily because of resource limitations. In the present study, we evaluated the effect on treatment decisions by oncologists in the community oncology setting of a brief geriatric assessment tool that estimates risk of toxicity.

Methods: This prospective longitudinal study in 5 community oncology practices in British Columbia involved patients 70 years of age and older starting a new cytotoxic chemotherapy regimen. Clinical personnel completed a brief validated geriatric assessment tool-the Cancer and Aging Research Group chemotherapy toxicity tool (carg-tt)-that estimates the risk of grade 3 or greater toxicity in older patients. Physicians were asked if the carg-tt changed their treatment plan or prompted extra supports. Patients were followed to assess the incidence of toxicity during treatment.

Results: The study enrolled 199 patients between July 2016 and February 2018. Mean age was 77 years. Treatment was palliative in 61.4% of the group. Compared with physician judgment, the carg-tt predicted higher rates of toxicity. In 5 patients, treatment was changed based on the carg-tt. In 38.5% of the patients, data from the tool prompted extra supports. Within the first 3 cycles of treatment, 21.3% of patients had experienced grade 3 or greater toxicity.

Conclusions: This study demonstrates that use of a brief geriatric assessment tool is possible in a broad community oncology practice. The tool modified the oncologist's supportive care plan for a significant number of older patients undertaking cytotoxic chemotherapy.

Keywords: Geriatric oncology; chemotherapy; elderly patients; geriatric assessment; toxicity.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.

Figures

FIGURE 1
FIGURE 1
Study procedure schema. BCCOT = British Columbia Community Oncology Clinical Trialists; CARG = Cancer and Aging Research Group.
FIGURE 2
FIGURE 2
Cancer and Aging Research Group Chemotherapy Toxicity Tool. GI = gastrointestinal; GU = genitourinary; chemo = chemotherapy. aRisk of grade 3 or greater toxicity.

Similar articles

Cited by

References

    1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–65. doi: 10.1200/JCO.2008.20.8983. - DOI - PubMed
    1. Hurria A, Dale W, Mooney M, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32:2587–94. doi: 10.1200/JCO.2013.55.0418. - DOI - PMC - PubMed
    1. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31. doi: 10.1200/JCO.2004.02.175. - DOI - PubMed
    1. Mariano C, Francl M, Pope J, Wong L, Lim HJ, Lohrisch C. Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials. Clin Breast Cancer. 2015;15:73–9. doi: 10.1016/j.clbc.2014.09.002. - DOI - PubMed
    1. Yonemori K, Hirakawa A, Komiyama N, et al. Participation of elderly patients in registration trials for oncology drug applications in Japan. Ann Oncol. 2010;21:2112–18. doi: 10.1093/annonc/mdq070. - DOI - PubMed

Publication types

Substances

LinkOut - more resources